Physician profile

Mark P Brooks

Obstetrics & Gynecology · Fishersville, VA

NPI 1023109725

$203.73

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$87.59

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amag Pharmaceuticals, INC. $32.55 2019
Astellas Pharma US INC $29.71 2024 Veozah
Mallinckrodt Hospital Products INC. $27.02 2020
Organon LLC $25.69 2024
Bayer Healthcare Pharmaceuticals INC. $18.10 2024
Abbvie INC. $17.69 2019
Pfizer INC. $14.09 2024
Hologic Sales and Service, LLC $14.03 2019
Alexion Pharmaceuticals, INC. $12.59 2019
Therapeuticsmd, INC. $12.26 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark P Brooks

$203.73

in general payments reported 2019-2025

Years
2019-2024
Top company
Amag Pharmaceuticals, INC.

https://glasscript.com/doctor/620035/mark-p-brooks

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.